ospemifene (osphena) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ospemifene (commercial name Osphena produced by Shionogi) is anoral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) that selectively binds to estrogen receptors and either stimulates or blocks estrogen's activity in different tissue types. It has an agonistic effect on the endometrium. It’s building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulval and vaginal atrophy”.   NCATS

Chemistry

  • SMILES: OCCOC1=CC=C(C=C1)C(=C(\CCCl)C2=CC=CC=C2)\C3=CC=CC=C3
  • InChIKey: LUMKNAVTFCDUIE-VHXPQNKSSA-N
  • Mol. Mass: 378.891
  • ALogP: 5.65
  • ChEMBL Molecule:
    ospemifene  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$5.1718 - $7.4135
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol | 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol | deamino-hydroxytoremifene | fc-1271 | fc-1271a | ospemifene | osphena | senshio | z-2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol

Organizations (8)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (3)


 

Atrophy

Dyspareunia

Menopause

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Atrophy (Phase 3)

Dyspareunia (Phase 4)

Menopause (Phase 4)

Sexual Dysfunction, Physiological (Phase 4)

Sexual Health (Phase 4)

Vaginal Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue